Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod

Table 1 Demographic features and anti-JCV antibody status of study participants

	MS patients (n = 128)
Sex, female	93 (72.7%)
Age, years	39 [IQR 32–48; range 20–70]
Disease duration, years	10 [IQR 5–16; range 0–43]
EDSS score	2.0 [IQR 1.0–3.5; range 0–8.0]
Lymphocyte counts at sampling, /μL	709 [IQR 447–1539; range 222–3491]
History of fingolimod usage	83 (64.8%)
Use of fingolimod at sampling^a	64 (50.0%)
Anti-JCV antibody, positive	86 (67.2%)
Anti-JCV antibody index	1.19 [IQR 0.21–3.09; range 0.06–4.04]

Values indicate the median [IQR and range] or count (%)
EDSS Expanded Disability Status Scale, IQR interquartile range, JCV JC virus, MS multiple sclerosis
^aOther disease-modifying drugs were used in 39 patients (30.5%) at sampling: interferon-β-1a in 15 (11.7%), dimethyl fumarate in 13 (10.2%), glatiramer acetate in 4 (3.1%), natalizumab in 3 (2.3%), interferon-β-1b in 2 (1.6%), azathioprine in 1 (0.8%), and methotrexate in 1 (0.8%)

ISSN: 1742-2094